iVascular Invests 15 Million In Catalonia Facilities

In addition to the project to expand the facility, iVascular anticipates that over the course of the next five years it will commit forty million euros to investments in research, development, and innovation (R&D&I) as well as its expansion of commercial operations on a global scale. Because the corporation places such strong emphasis on its leading role in the field of cardiovascular pathology, it allocates fifteen percent of its annual revenue to research, development, and innovation each year. iVascular increases its facilities in Catalonia. The Sant Vicenc del Horts facility will receive an investment of 15 million euros from the Spanish corporation that is responsible for the development of medical equipment (Barcelona).

The investment intends to triple the plant’s current surface area, with more than 1,700 square meters being allocated to ISO 7 rooms and more than 400 square meters being allocated to ISO 8 rooms. This will enable the plant to increase its production capacity by a factor of six and continue to expand at an exponential rate. The expansion of iVascular’s facilities is a direct response to the necessity of increasing the company’s manufacturing capacity in order to keep up with this growth rate.

According to a press release issued by the company that manufactures medical devices, thanks to this investment initiative, the company will also enhance its human workforce, which is presently comprised of more than 350 individuals. In addition to the project to expand the facility, iVascular anticipates that over the course of the next five years it will commit forty million euros to investments in research, development, and innovation (R&D&I) as well as its expansion of commercial operations on a global scale.

Because the corporation places such strong emphasis on its leading role in the field of cardiovascular pathology, it allocates fifteen percent of its annual revenue to research, development, and innovation each year. The primary mission of iVascular is to offer technological solutions to medical professionals so that those experts can provide the highest quality care to their patients in the shortest amount of time. The company is responsible for the design, production, and distribution of over 1,500 cutting-edge medical products. The company’s stents, balloons, and catheters are utilized in hospitals all over the world, and they anticipate that by the year 2025, they will have enhanced the quality of life for more than two million individuals.

iVascular improves the qualities of its medical devices by fashioning metal tubes into stents, transforming plastic pellets into catheters, and designing its own polymers to use in the manufacturing process. The company’s goods are accepted in over 80 countries throughout the world, accounting for 90% of the company’s total exports.

This year, the corporation anticipates that its revenue will rise to more than 50 million Euros. If this figure holds true for 2021, it would indicate an increase in sales of more than 30 percent. iVascular’s revenue for the previous year came in at €38.5 million. Since its inception in 2010, this company has placed its primary emphasis on the treatment of vascular disorders in the fields of interventional cardiology, endovascular interventionism, and neuroradiology respectively.

Advertisement